Cargando…

Somatostatin binding in normal and malignant human gastrointestinal mucosa.

Somatostatin is a regulatory peptide implicated in the control of cellular proliferation in epithelial tissues and this regulation may occur directly via membrane bound receptor activation. The aim of this study was to investigate somatostatin binding in human gastrointestinal cancer and normal muco...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, G. V., Farmery, S. M., Woodhouse, L. F., Primrose, J. N.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977804/
https://www.ncbi.nlm.nih.gov/pubmed/1354473
_version_ 1782135340610355200
author Miller, G. V.
Farmery, S. M.
Woodhouse, L. F.
Primrose, J. N.
author_facet Miller, G. V.
Farmery, S. M.
Woodhouse, L. F.
Primrose, J. N.
author_sort Miller, G. V.
collection PubMed
description Somatostatin is a regulatory peptide implicated in the control of cellular proliferation in epithelial tissues and this regulation may occur directly via membrane bound receptor activation. The aim of this study was to investigate somatostatin binding in human gastrointestinal cancer and normal mucosa. Plasma membranes were prepared from specimens of tumour and normal mucosa from 51 patients undergoing surgical resection for malignancy (28 gastric, 23 colorectal). Using a competitive displacement assay, specific 125I-tyrosine-11-somatostatin-14 binding to plasma membranes was assessed and and characterised in terms of receptor affinity (Kd) and maximum binding capacity (Bmax) as determined by Scatchard analysis. Specific low affinity (Kd = 166 nM), high capacity (Bmax = 1.2 pmol mg-1 protein) somatostatin binding was demonstrated in 22 of the gastric cancers and 17 of the colorectal cancers (Kd = 140 nM, Bmax = 1.8 pmol mg-1 protein). Similar affinity and binding capacity was demonstrable in normal mucosal samples. High affinity receptors for somatostatin were expressed by one gastric carcinoma (Kd = 0.9 nM; Bmax = 0.23 pmol mg-1 protein). Thus, low affinity, high capacity binding is a common feature of gastrointestinal tumours and normal mucosa, and high affinity receptors may occasionally be demonstrated. The functional significance of these low affinity binding sites requires elucidation to determine whether long-acting somatostatin analogues may have therapeutic benefit in gastrointestinal malignancy.
format Text
id pubmed-1977804
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19778042009-09-10 Somatostatin binding in normal and malignant human gastrointestinal mucosa. Miller, G. V. Farmery, S. M. Woodhouse, L. F. Primrose, J. N. Br J Cancer Research Article Somatostatin is a regulatory peptide implicated in the control of cellular proliferation in epithelial tissues and this regulation may occur directly via membrane bound receptor activation. The aim of this study was to investigate somatostatin binding in human gastrointestinal cancer and normal mucosa. Plasma membranes were prepared from specimens of tumour and normal mucosa from 51 patients undergoing surgical resection for malignancy (28 gastric, 23 colorectal). Using a competitive displacement assay, specific 125I-tyrosine-11-somatostatin-14 binding to plasma membranes was assessed and and characterised in terms of receptor affinity (Kd) and maximum binding capacity (Bmax) as determined by Scatchard analysis. Specific low affinity (Kd = 166 nM), high capacity (Bmax = 1.2 pmol mg-1 protein) somatostatin binding was demonstrated in 22 of the gastric cancers and 17 of the colorectal cancers (Kd = 140 nM, Bmax = 1.8 pmol mg-1 protein). Similar affinity and binding capacity was demonstrable in normal mucosal samples. High affinity receptors for somatostatin were expressed by one gastric carcinoma (Kd = 0.9 nM; Bmax = 0.23 pmol mg-1 protein). Thus, low affinity, high capacity binding is a common feature of gastrointestinal tumours and normal mucosa, and high affinity receptors may occasionally be demonstrated. The functional significance of these low affinity binding sites requires elucidation to determine whether long-acting somatostatin analogues may have therapeutic benefit in gastrointestinal malignancy. Nature Publishing Group 1992-08 /pmc/articles/PMC1977804/ /pubmed/1354473 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Miller, G. V.
Farmery, S. M.
Woodhouse, L. F.
Primrose, J. N.
Somatostatin binding in normal and malignant human gastrointestinal mucosa.
title Somatostatin binding in normal and malignant human gastrointestinal mucosa.
title_full Somatostatin binding in normal and malignant human gastrointestinal mucosa.
title_fullStr Somatostatin binding in normal and malignant human gastrointestinal mucosa.
title_full_unstemmed Somatostatin binding in normal and malignant human gastrointestinal mucosa.
title_short Somatostatin binding in normal and malignant human gastrointestinal mucosa.
title_sort somatostatin binding in normal and malignant human gastrointestinal mucosa.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977804/
https://www.ncbi.nlm.nih.gov/pubmed/1354473
work_keys_str_mv AT millergv somatostatinbindinginnormalandmalignanthumangastrointestinalmucosa
AT farmerysm somatostatinbindinginnormalandmalignanthumangastrointestinalmucosa
AT woodhouself somatostatinbindinginnormalandmalignanthumangastrointestinalmucosa
AT primrosejn somatostatinbindinginnormalandmalignanthumangastrointestinalmucosa